Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients (EVOLUTION)
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
The trial is a double-blinded randomized study with three arms: Golimumab (GOL) 50 mg
subcutaneous injection every 4 weeks, guselkumab (GUS) 100 mg subcutaneous injection every 8
weeks, and GUS 100 mg every 4 weeks. It will examine whether switching to a selective IL23
inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among
patients with PsA who have an inadequate response to a TNFi